ReachBio, LLC Launched by Experienced Stem Cell Management Team

ReachBio LLC announced today the official opening of its business operations. The company will focus on providing specialized contract assay and contract research services utilizing in vitro and in vivo stem cell and progenitor cell assays to biopharma, biotechnology, agri-chemical, and other related industries. In particular, the company will draw on their unique depth of experience in clinical and industrial stem cell and progenitor cell biology to offer services for evaluating the toxic, inhibitory or stimulatory effects of compounds on hematopoietic and non-hematopoietic cells.

These sensitive, multiparametric high-content assays can evaluate such things as bone marrow toxicity (hematotoxicity, myelotoxicity, lymphotoxicity, neutropenia, etc.), stem cell engraftment kinetics, maximum tolerated dose, and colony forming cell (CFC) content in clinical samples (i.e., cord blood, disease-specific samples and samples from patients undergoing clinical trials). ReachBio will also offer assay design and validation services, as well as a unique on-site contract assay service for clients with particularly demanding assay requirements.
 
ReachBio, LLC Launched by Experienced Stem Cell Management Team
(newswiretoday.com)